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Abstract
Thymosin beta-4 (Tb4) is a ubiquitous protein with many properties relating to cell proliferation and differentiation that
promotes wound healing and modulates inflammatory mediators. We studied the effects of chronic administration of Tb4
on the skeletal and cardiac muscle of dystrophin deficient mdx mice, the mouse model of Duchenne muscular dystrophy.
Female wild type (C57BL10/ScSnJ) and mdx mice, 8–10 weeks old, were treated with 150 mgo fT b4 twice a week for 6
months. To promote muscle pathology, mice were exercised for 30 minutes twice a week. Skeletal and cardiac muscle
function were assessed via grip strength and high frequency echocardiography. Localization of Tb4 and amount of fibrosis
were quantified using immunohistochemistry and Gomori’s tri-chrome staining, respectively. Mdx mice treated with Tb4
showed a significant increase in skeletal muscle regenerating fibers compared to untreated mdx mice. Tb4 stained
exclusively in the regenerating fibers of mdx mice. Although untreated mdx mice had significantly decreased skeletal muscle
strength compared to untreated wild type, there were no significant improvements in mdx mice after treatment. Systolic
cardiac function, measured as percent shortening fraction, was decreased in untreated mdx mice compared to untreated
wild type and there was no significant difference after treatment in mdx mice. Skeletal and cardiac muscle fibrosis were also
significantly increased in untreated mdx mice compared to wild type, but there was no significant improvement in treated
mdx mice. In exercised dystrophin deficient mice, chronic administration of Tb4 increased the number of regenerating fibers
in skeletal muscle and could have a potential role in treatment of skeletal muscle disease in Duchenne muscular dystrophy.
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Introduction
Duchenne muscular dystrophy (DMD) is an inherited X-linked
disorder with an incidence of 1 in 3,500 male births that is due to
the absence of dystrophin, a large protein linking the intracellular
cytoskeleton to the extracellular matrix.[1] The animal model of
DMD, the mdx mouse, is genetically similar to the human
deletion.[1–3] Although the underlying gene defect is the same in
human and the mdx mouse, the clinical picture is quite different.
The mdx skeletal muscle undergoes an early acute phase of
degeneration at 3–4 weeks of age followed by a successful
regeneration phase. The histopathology after this acute phase
shows a relatively mild picture, although specific muscles (e.g.
diaphragm) and older mice can show more severe pathology
consistent with human DMD muscle at presentation (failed
regeneration and fibrosis). Commensurate with the pathology,
the physical symptoms of the mdx mouse tend to be relatively mild,
with muscle weakness more obvious after exercise or lengthening
contractions.[4–6] Mdx mice also develop decreased cardiac
systolic function slowly over time. This decreased function can
be measured at significant levels by non-invasive echocardiogra-
phy around nine months of age.[7,8]
In order to identify new potential therapeutic agents, studies
have looked at skeletal muscle gene expression profiles in mdx mice
during disease progression. [9–17] Thymosin beta-4 (Tb4) was one
gene with increased expression in dystrophin deficient skeletal
muscle cells and may play a role in compensatory path-
ways.[11,16–18] Tb4 is a peptide of 43 amino acids that was
first isolated from the thymus gland and subsequently found to be
ubiquitous in nature.[19–21] Tb4 functions mainly as an actin-
sequestering molecule regulating cell migration, proliferation and
differentiation.[22–25] It also promotes wound healing and
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shown to promote cardiomyocyte migration, survival and repair
in a coronary ligation model.[28]. Based on these mechanisms, we
studied the effects of chronic Tb4 administration on skeletal and
cardiac muscle function in exercised dystrophin deficient mice.
While we found no significant differences in muscle function, we
did see significantly increased skeletal muscle regeneration in Tb4
treated mdx mice and these regenerating fibers distinctly stained for
Tb4.
Methods
Animal Care
All animals were handled in strict accordance with good animal
practice as defined by the relevant national and/or local animal
welfare bodies, and all animal work was approved by the
Institutional Animal Care and Use Committee at the Children’s
National Medical Center, Washington, DC and the Veterans
Administration Medical Center, Washington, DC (Protocol
#01079). Eight to ten week old female C57BL/10ScSn-
Dmd
mdx/J (mdx) and C57BL/10ScSnJ (wild type) mice weighing
20–30 grams were purchased from The Jackson Laboratory (Bar
Harbor, Ma). All mice were housed in an individually vented cage
system with a 12 hour light-dark cycle and received standard
mouse chow and water ad libitum. All mice were rested at least 10–
14 days before starting acclimations and baseline recordings.
Treatment with Thymosin Beta-4
Tb4 (RegeneRx Biopharmaceuticals Inc., Bethesda, Md) was
given via intraperitoneal injection twice weekly over a 6 month
period to mdx and wild type mice at a dose of 150 mg in 200 ml
PBS. Buffer was given at the same times to mdx and wild type
control groups.
Treadmill Exercise
The treadmill exercise uses a common commercially available
setup (Columbus Instruments, Columbus, Ohio) which employs a
moving belt. We subjected all experimental mice to a 30-minute
run on a horizontal treadmill at 12 m/min, twice a week. This test
was performed during the morning hours twice weekly during the
6 months except in those days on which functional data was
obtained.
Grip Strength Test
Grip Strength was assessed using a grip strength meter
consisting of horizontal forelimb mesh and an angled hind limb
mesh (Columbus Instruments, Columbus, OH). Five successful
hindlimb and forelimb strength measurements within 2 minutes
were recorded and normalized to body weight as previously
described.[29]
Rotarod Test
Mice were trained on the Rotarod (Ugo Basile, VA, Italy) for
two days before collecting data. Each acclimatization session
consisted of four training sessions, 2 per day and each session
lasting 120 seconds at a speed of 5 rpm. Each trial consisted of
placing the mice on the rod at 10 rpm for 60 seconds (stabilizing
period) followed by an acceleration from 10 rpm to 40 rpm within
the first 25 seconds until the animal falls from the rod or until 180
seconds are reached. If the animals fell during the stabilizing
period, they were placed back on the rod to complete the session.
The total testing time is 240 seconds (60 sec stabilization time and
180 seconds test time). Each trial was done twice a day (a gap of
2 h interval between sessions) for 3 consecutive days. The latency
to fall (seconds) was recorded and all six scores per mouse were
averaged and recorded as latency to fall (in seconds) for each
mouse.
Echocardiography
Mice were anesthetized with 1–2% isoflurane in 100% oxygen
and scanning was performed over 20 minutes using a high
frequency ultrasound probe (RMZ 702a, Vevo 660, VisualSonics,
Toronto, Canada) as previously described.[8] Qualitative and
quantitative measurements were made offline using analytic
software (VisualSonics, Toronto, Canada).
Histological Evaluations
At the end of the trial, all animals were euthanized and tissue
samples were taken for further testing. Histological evaluations
were done by two individuals in a blinded manner using coded
H&E stained slides and their results were averaged. The number
of tissues examined per group varied based on tissue availability.
Quantitative stereology (Olympus C.A.S.T. Stereology System,
Olympus America Inc., Center Valley, PA) was used to evaluate
the slides. Assessment criteria included: assessment of total fibers
present, total fibers with central nuclei, total peripheral nuclei,
total central nuclei, regenerating fibers (highly basophilic fibers),
degenerating fibers, and inflammation (an interstitial group of
more than 10 smaller inflammatory cell dark blue nuclei in a high
power field) in five high power (40x) non-overlapping fields in
normal and mdx gastrocnemius muscle sections. Fibers intersecting
the left and top borders of the field where not counted and nuclei
further than one nuclear diameter from the fiber border were
deemed ‘‘central’’.[29]
For immunohistochemistry, tissue slides of untreated mdx
gastrocnemius skeletal muscle were deparaffinized and hydrated.
For antigen retrieval, slides were immersed in citrate buffer
(0.01 M, pH 6.0) and heated twice in a microwave (700 W or
high) for 5 min. The slides were quenched with endogenous
peroxidase by incubation with 3% hydrogen peroxide solution for
5 minutes and washed three times in PBS for 5 minutes. Slides
were then immunostained with rabbit polyclonal antibody to
thymosin b4 (1:2000 dilution; ALPCO Diagnostics, Windham,
NH, USA) at 4uC overnight. After primary antibody incubation,
slides were washed three times in PBS for 5 minutes and incubated
with secondary antibody for 1 hour. Then, slides were washed
four times in PBS for 5 minutes each and the color reaction was
developed with DAB and slides were counterstained Meyer’s
hematoxylin (DAKO, Carpinteria, CA, USA) for 20 seconds,
dehydrated, and mounted with Permount (Fisher Scientific,
Pittsburgh, PA, USA).
Quantification of Fibrosis
Using gastrocnemius, diaphragm and cardiac muscle tissue
from treated and untreated wild type and mdx mice, five
paraffin embedded sections for each group were stained with
hematoxylin and eosin (H&E) (Sigma, St. Louis, Mo) and
Gomori’s Tri-Chrome stain containing: fast green FCF,
chromotrope 2R, and phosphotungstic acid (Sigma, St. Louis,
Mo). The tissue was imaged under a light microscope at 10X
and digital images were obtained using computer software
(Olympus C.A.S.T. Stereology System, Olympus America Inc.,
Center Valley, PA). The digital images were copied into NIH
Image J program and threshold set to separate blue staining
collagen from red staining muscle tissues. The total area of blue
staining collagen was then expressed as a percent of total tissue
area in the image.
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Blood was obtained by heart puncture immediately after
euthanasia. 250 mL of blood was collected into eppendorf tubes,
allowed to clot and kept at room temperature to allow clot-
contraction prior to centrifugation and serum collection. CK
determination was performed according to the manufacturer’s
instructions using standard spectrophotometric method with
enzyme-coupled assay reagent from Fisher Scientific (CK10).[30]
Absorption at 340 nm was measured every min for 2 min at 37uC
to calculate enzyme activity. Duplicate measurements were done
on each serum sample and the data was expressed as U/L.
Statistical Analysis
Measurements between wild type and mdx mice were compared
at each time point using an analysis of variance with Sidak
adjustment for multiple comparisons (body weight, GSM,
Rotarod, echocardiography, percent collagen). Normality of each
quantitative measurement was confirmed prior to analysis and
those not conforming to normality underwent data transforma-
tions. Histology measurements (degeneration fibers, regenerating
fibers, inflammation, calcification, and central and peripheral
nuclei) were first compared between two investigators to determine
their consistency. Comparisons were then made using Poisson
regression or using negative binomial regression where the Poisson
model did not fit the data due to over dispersion.
Results
Both wild type and mdx mice were treated with Tb4 for 6
months and the behavioral data was collected at baseline (3
months of age), mid trial (5–6 months of age), and end of the trial
(9 months of age). All results are presented as mean 6 standard
deviation except those in figures 1 and 2.
Body Weight
No significant differences were seen in body weights between
treated and untreated mice within the same strain. When
comparing mdx and wild type mice, there was a significant
increase in the body weight of mdx mice at baseline and 6 months
but not at 9 months of age (Table S1).
Grip Strength
Untreated mdx mice had significantly decreased normalized
forelimb grip strength (kilogram force per kilogram; KGF/kg)
compared to untreated wild type mice at 3, 6 and 9 months of age.
Comparing the normalized hindlimb grip strength of these same
groups showed a significant decrease in mdx mice at 3 and 6
months but not at 9 months of age. There were no significant
differences in normalized forelimb or hindlimb grip strength
between treated and untreated mice within the same strain during
the trial (Table S1).
Rotarod
There were no significant differences in latency time to fall on
the Rotarod apparatus between wild type and mdx mice. There
were also no differences between treated and untreated mice
within the strain, but treated mdx mice showed significantly lower
performance in comparison with treated wild type mice at 9
months of age (Table S1).
Echocardiography
High frequency echocardiography found decreased cardiac
function, measured as percent shortening fraction, in untreated
mdx (27.961.86%) mice compared to untreated (30.662.6%) and
treated (32.065.2; p=0.045) wild type mice (Figure 1). Treated
mdx (26.263.1%) mice also showed significantly decreased cardiac
function compared to treated (p,0.01) and untreated (p,0.05)
wild type mice. There were no significant differences between
treated and untreated mice within the same strain. No significant
differences were found in measurements of left ventricular
chamber size or wall thickness between mdx and wild type mice,
showing no dilation in the hearts of mdx mice with decreased
Figure 1. Significantly decreased cardiac function (mean 6
SEM) measured as percent shortening fraction (%SF) in mdx
mice is seen after 6 months of treatment with thymosin-beta 4
compared to wild type mice. There is no significant difference
between treated and untreated mdx mice.
doi:10.1371/journal.pone.0008976.g001
Figure 2. Significantly increased percent collagen (mean 6 SEM) for cardiac (n=3 for treated and untreated mdx mice and
untreated wild type, n=4 for treated wild type; panel A), diaphragm (n=5 for all groups; panel B), and gastrocnemius (n=3 for all
groups; panel C) is seen in mdx mice compared to wild type. There was no significant difference between treated and untreated mdx mice.
doi:10.1371/journal.pone.0008976.g002
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Doppler measurements of aortic, pulmonary, tricuspid or mitral
blood flow velocities between treated and untreated mdx mice
(Table S2).
Skeletal Muscle Histology
Evaluation of the gastrocnemius skeletal muscle histology found
significantly increased number of regenerating fibers in treated mdx
mice (11.6613.5) compared to untreated mdx mice (2.661.1;
p=0.03). Both treated and untreated mdx mice had increased
central nuclei, central nuclei per fiber and central nucleated fibers
compared to treated and untreated wild type. Untreated mdx mice
showed significantly increased total peripheral nuclei compared to
treated mdx mice (p=0.014). There was also significantly increased
inflammation (3+) between mdx and wild type mice that was not
significantly altered in the treated groups (Table S3).
Quantification of Fibrosis
Using Gomori’s tri-chrome staining, an analysis of percent
collagen showed significantly increased collagen found in the left
ventricles of untreated (3.8360.9%) and treated (4.3961.2%) mdx
mice compared to both untreated (1.661.1%) and treated
(1.8260.9%) wild type controls (all p values,0.05) (Figures 2
and 3). The diaphragm also showed significantly increased percent
collagen in the untreated (22.967.5%) and treated (25.066.6%)
mdx mice compared to untreated (7.460.8%) and treated
(7.961.8%) control mice (all p values,0.01). The gastrocnemius
also showed significantly increased percent collagen in untreated
mdx mice (6.2561.7%) compared to untreated control mice
(3.061.1%; p,0.05) (Figure 2). There were no significant
differences in percent collagen between treated and untreated
groups within the same strain.
Serum Creatine Kinase
There was a significant increase in serum creatine kinase in both
treated (520561785 U/L, n=8) and untreated (578862494 U/
L, n=10) mdx mice compared to treated (1416108 U/L, n=14)
and untreated (85675 U/L, n=13) wild type controls (p,0.001).
There was no significant difference between treated and untreated
mdx mice.
Tb4 Localization Using Immunohistochemistry
Staining of untreated wild type and mdx skeletal muscle
(gastrocnemius) with anti-Tb4 antibody shows localized staining in
regenerating fibers. Sequential slides were stained for desmin, a
marker for regenerating fibers, and this staining corresponded to
Tb4 staining. There was no staining of fibers with either anti-Tb4
or anti-desmin antibodies in wild type tissue (Figure 4).
Discussion
We completed a six month trial using Tb4 in exercised mdx and
wild type mice. We found no significant improvement in treated
mdx skeletal or cardiac muscle function compared to untreated mdx
mice. However, we did find significantly increased regenerating
fibers in treated mdx skeletal muscle and these fibers convincingly
stained for Tb4. While Tb4 led to increased regeneration in mdx
skeletal muscle, it did not improve fibrosis in the cardiac,
diaphragmatic or skeletal muscle of treated mdx mice. This study
shows that chronic Tb4 administration is beneficial for skeletal
muscle fiber regeneration in dystrophin deficient mice.
Previous gene profiling experiments showed increased Tb4
expression in skeletal muscle of mdx mice. Tseng et al. (2002)
showed that in 16 week old mdx mice, the gastrocnemius muscle
showed a two-fold increase in Tb4 mRNA expression. Boer et al.
(2002) showed that another member of the thymosin family with
similar properties, thymosin beta-10, showed a 4-fold increased
expression in 13–15 week old mdx gastrocnemius muscle compared
to wild type.[9] Nakayama et al. (2004) found up-regulation of Tb4
in2 month oldmdxhindlimb skeletal muscle cell culture and showed
that it was not altered after the addition of micro-dystrophin to the
Figure 3. Gomori’s tri-chrome stained slides of cardiac tissue
showing increased fibrosis in mdx mice. A) Untreated wild type
cardiac tissue showing minimal collagen staining (light blue color)
corresponding to a percent collagen of 1.8260.5%. B) Untreated mdx
cardiac tissue showing diffuse fibrosis in the LV and RV ventricular walls
corresponding to a percent collagen of 3.8360.5%. C) Tb4 treated wild
type mice showing few increased areas of collagen staining corre-
sponding to a percent collagen of 1.660.5%. D) Tb4 treated mdx
cardiac tissue showing large areas of collagen staining in the LV and RV
walls corresponding to a percent collagen of 4.3960.7%. (LV – left
ventricle, RV – right ventricle).
doi:10.1371/journal.pone.0008976.g003
Figure 4. Peroxidase staining of regenerating fibers using anti-
TB4 antibodies in skeletal muscle (gastrocnemius). A) Mdx
muscle treated with anti-TB4 antibody shows peroxidase staining of
regenerating fibers (*); B) Mdx muscle treated with anti-desmin
antibody shows staining in regenerating fibers (#), the same as in
plate A; C) Wild type muscle treated with anti-TB4 antibodies shows no
staining; D) Wild type muscle treated with anti-desmin antibodies
shows no staining.
doi:10.1371/journal.pone.0008976.g004
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DMDpatientderivedcelllines.Turketal.(2005)foundsignificantly
increased prothymosinbeta-4(Ptmb4), the precursor protein,at 8 of
9 time points ranging from 1 to 20 weeks in mdx hindlimb
muscle.[17] Hara et al. (2005) found up-regulation of Tb4
expression in mdx skeletal muscle cell cultures and that Tb4
stimulated migration and chemotaxis of myoblasts.[18] All of these
studies used mice from 1 to 20 weeks old, a time period of rapid
degeneration and regeneration in the mdx skeletal muscle and
demonstrate that Tb4 is important in skeletal muscle regenerative
pathways. Our study supports these previous reports. We
demonstrate the presence of Tb4 in regenerating fibers (Figure 4)
of mdx gastrocnemius muscle. We also showed a significantly
increased number of regenerating fibers in the gastrocnemius of
Tb4 treated mdx mice (Table S3). This parameter has significant
variation because the gastrocnemius muscle develops patchy areas
ofregeneration andthemajorityofthe muscle that issampled shows
no areas of regeneration at all. In another study, Tb4 stimulated the
migration of stem cells in hair follicles leading to increased hair
growth. [31] Tb4 may likewise stimulate satellite cell migration in
skeletalmusclecells,leading toimprovedregeneration.Importantly,
this is the first correlation of gene expression data with in vivo
administration and histological localization and supports an integral
role for Tb4 in muscle regeneration.
Another potential mechanism of Tb4 mediated regeneration is
the inhibition of apoptosis. Tb4 was shown to decrease apoptosis
in an ethanol-treated corneal epithelial model and inhibit
activation of NF-kB during TNF-a stimulation in human corneal
epithelial cells. [32,33] In cardiac tissue, Bock-Marquette et al.
(2004) showed that Tb4 decreased cardiac fibrosis secondary to
ischemic damage in a coronary ligation model. This beneficial
effect of Tb4 on myocyte cell survival was also related to decreased
apoptosis and found to be mediated by PINCH, ILK and Akt. [28]
Previous C2C12 muscle cell culture experiments from our lab also
showed that Tb4 directly decreased NF-kB activation from TNF-a
stimulation. [34] These studies support the direct action of Tb4o n
muscle cells to inhibit NF-kB and consequently apoptosis and
potentially improve muscle regenerative capacity.
Studies of Tb4 in multiple tissue models showed modulation of
various inflammatory cytokines. [35–37] While, these changes
may acutely promote wound healing, the effects of chronic Tb4
treatment on different cytokine levels are not known. Chronic
treatment could induce a more prolonged cytokine response that
may become more pro-inflammatory and pro-fibrotic, decreasing
the beneficial effects seen with acute Tb4 administration. This
might explain why this study found no significant changes in the
amounts of collagen in skeletal and cardiac muscle in chronically
Tb4 treated mdx mice.
Also, previous studies showed that decreased levels of Ac-
SDKP, the active tetrapeptide that is released from Tb4, led to
increased cardiac and renal perivascular fibrosis.[38] Pokharel
et al. (2004) also showed that in rats over-expressing angiotensin-
converting enzyme, which decreases levels of Ac-SDKP, there was
increased cardiac collagen content.[39] Thus, the chronic
exposure of cardiac and skeletal muscle to Tb4 may lead to a
down-regulation of Tb4 expression or receptor activity and a
decrease in Ac-SDKP.
Although we did not directly measure Tb4 levels in treated
mice, a previous study showed significantly increased levels in the
hearts and skeletal muscle of mice after treatment with 400
micrograms of Tb4 via intraperitoneal injection.[40] Chronic
exposure of Tb4 could potentially lead to the development of anti-
Tb4 antibodies. These antibodies could neutralize Tb4 and
prevent any beneficial effects on cell survival and decreased
fibrosis. The presence of any antibodies was not assessed in this
study.
This study found a significant increase in Tb4 positive
regenerating fibers in the skeletal muscle of exercised mdx mice.
There were no beneficial effects of chronic Tb4 treatment on
muscle function or fibrosis. This study provides histological
correlation for previous gene expression studies showing the
importance of Tb4 in skeletal muscle regeneration.
Supporting Information
Table S1 Body weight, normalized grip strength, and Rotarod
latency to fall measurements in treated and untreated wild type
(BL10) and mdx mice after 6 months of treatment with thymosin
beta-4.
Found at: doi:10.1371/journal.pone.0008976.s001 (0.05 MB
DOC)
Table S2 Cardiac M-mode and spectral Doppler echocardiog-
raphy measurements in treated and untreated wild type (BL10)
and mdx mice after 6 months of treatment with thymosin beta-4.
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DOC)
Table S3 Gastrocnemius skeletal muscle histology measure-
ments in treated and untreated wild type (BL10) and mdx mice
after 6 months of treatment with thymosin beta-4.
Found at: doi:10.1371/journal.pone.0008976.s003 (0.04 MB
DOC)
Author Contributions
Conceived and designed the experiments: CFS EH KN. Performed the
experiments: CFS HJC AS GP EP ADG EH KN. Analyzed the data: CFS
HJC AS GP EP ADG HGD EH KN. Contributed reagents/materials/
analysis tools: CFS HJC GP EP HGD. Wrote the paper: CFS ADG HGD
KN.
References
1. Hoffman EP, Brown RH Jr, Kunkel LM (1987) Dystrophin: the protein product
of the Duchenne muscular dystrophy locus. Cell 51: 919–928.
2. Ryder-Cook AS, Sicinski P, Thomas K, Davies KE, Worton RG, et al. (1988)
Localization of the mdx mutation within the mouse dystrophin gene. EMBO J 7:
3017–3021.
3. Sicinski P, Geng Y, Ryder-Cook AS, Barnard EA, Darlison MG, et al. (1989)
The molecular basis of muscular dystrophy in the mdx mouse: a point mutation.
Science 244: 1578–1580.
4. Anderson JE, Bressler BH, Ovalle WK (1988) Functional regeneration in the
hindlimb skeletal muscle of the mdx mouse. J Muscle Res Cell Motil 9: 499–515.
5. De Luca A, Pierno S, Liantonio A, Cetrone M, Camerino C, et al. (2003)
Enhanced dystrophic progression in mdx mice by exercise and beneficial effects
of taurine and insulin-like growth factor-1. J Pharmacol Exp Ther 304: 453–463.
6. Lefaucheur JP, Pastoret C, Sebille A (1995) Phenotype of dystrophinopathy in
old mdx mice. Anat Rec 242: 70–76.
7. Quinlan JG, Hahn HS, Wong BL, Lorenz JN, Wenisch AS, et al. (2004)
Evolution of the mdx mouse cardiomyopathy: physiological and morphological
findings. Neuromuscul Disord 14: 491–496.
8. Spurney CF, Knoblach S, Pistilli EE, Nagaraju K, Martin GR, et al. (2008)
Dystrophin-deficient cardiomyopathy in mouse: expression of Nox4 and Lox are
associated with fibrosis and altered functional parameters in the heart.
Neuromuscul Disord 18: 371–381.
9. Boer JM, de Meijer EJ, Mank EM, van Ommen GB, den Dunnen JT (2002)
Expression profiling in stably regenerating skeletal muscle of dystrophin-deficient
mdx mice. Neuromuscul Disord 12 Suppl 1: S118–124.
10. Marotta M, Ruiz-Roig C, Sarria Y, Peiro JL, Nunez F, et al. (2009) Muscle
genome-wide expression profiling during disease evolution in mdx mice. Physiol
Genomics 37: 119–132.
11. Nakayama Y, Nara N, Kawakita Y, Takeshima Y, Arakawa M, et al. (2004)
Cloning of cDNA encoding a regeneration-associated muscle protease whose
Tb4 Treatment in Mdx Mice
PLoS ONE | www.plosone.org 5 January 2010 | Volume 5 | Issue 1 | e8976expression is attenuated in cell lines derived from Duchenne muscular dystrophy
patients. Am J Pathol 164: 1773–1782.
12. Porter JD, Khanna S, Kaminski HJ, Rao JS, Merriam AP, et al. (2002) A
chronic inflammatory response dominates the skeletal muscle molecular
signature in dystrophin-deficient mdx mice. Hum Mol Genet 11: 263–272.
13. Porter JD, Merriam AP, Leahy P, Gong B, Feuerman J, et al. (2004) Temporal
gene expression profiling of dystrophin-deficient (mdx) mouse diaphragm
identifies conserved and muscle group-specific mechanisms in the pathogenesis
of muscular dystrophy. Hum Mol Genet 13: 257–269.
14. Porter JD, Merriam AP, Leahy P, Gong B, Khanna S (2003) Dissection of
temporal gene expression signatures of affected and spared muscle groups in
dystrophin-deficient (mdx) mice. Hum Mol Genet 12: 1813–1821.
15. Rouger K, Le Cunff M, Steenman M, Potier MC, Gibelin N, et al. (2002)
Global/temporal gene expression in diaphragm and hindlimb muscles of
dystrophin-deficient (mdx) mice. Am J Physiol Cell Physiol 283: C773–784.
16. Tseng BS, Zhao P, Pattison JS, Gordon SE, Granchelli JA, et al. (2002)
Regenerated mdx mouse skeletal muscle shows differential mRNA expression.
J Appl Physiol 93: 537–545.
17. Turk R, Sterrenburg E, de Meijer EJ, van Ommen GJ, den Dunnen JT, et al.
(2005) Muscle regeneration in dystrophin-deficient mdx mice studied by gene
expression profiling. BMC Genomics 6: 98.
18. Hara T, Nakayama Y, Nara N (2005) [Regenerative medicine of skeletal
muscle]. Rinsho Shinkeigaku 45: 880–882.
19. Oates K, Goldstein A (1995) Thymosin. In: DeVita VT, Hellman S,
Rosenberg SA, eds (1995) Biologic Therapy of Cancer. Philadelphia: JB
Lippincott. pp 841–852.
20. Pantaloni D, Carlier MF (1993) How profilin promotes actin filament assembly
in the presence of thymosin beta 4. Cell 75: 1007–1014.
21. Weber A, Nachmias VT, Pennise CR, Pring M, Safer D (1992) Interaction of
thymosin beta 4 with muscle and platelet actin: implications for actin
sequestration in resting platelets. Biochemistry 31: 6179–6185.
22. Hannappel E, Huff T (2003) The thymosins. Prothymosin alpha, parathymosin,
and beta-thymosins: structure and function. Vitam Horm 66: 257–296.
23. Safer D, Elzinga M, Nachmias VT (1991) Thymosin beta 4 and Fx, an actin-
sequestering peptide, are indistinguishable. J Biol Chem 266: 4029–4032.
24. Safer D, Golla R, Nachmias VT (1990) Isolation of a 5-kilodalton actin-
sequestering peptide from human blood platelets. Proc Natl Acad Sci U S A 87:
2536–2540.
25. Sanders MC, Goldstein AL, Wang YL (1992) Thymosin beta 4 (Fx peptide) is a
potent regulator of actin polymerization in living cells. Proc Natl Acad Sci U S A
89: 4678–4682.
26. Malinda KM, Sidhu GS, Mani H, Banaudha K, Maheshwari RK, et al. (1999)
Thymosin beta4 accelerates wound healing. J Invest Dermatol 113: 364–368.
27. Sosne G, Szliter EA, Barrett R, Kernacki KA, Kleinman H, et al. (2002)
Thymosin beta 4 promotes corneal wound healing and decreases inflammation
in vivo following alkali injury. Exp Eye Res 74: 293–299.
28. Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D (2004)
Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell
migration, survival and cardiac repair. Nature 432: 466–472.
29. Spurney CF, Gordish-Dressman H, Guerron AD, Sali A, Pandey GS, et al.
(2009) Preclinical drug trials in the mdx mouse: Assessment of reliable and
sensitive outcome measures. Muscle Nerve 39: 591–602.
30. Tietz N (1982) Fundamentals of clinical chemistry. Philadelphia: WB Saunders
Co. pp 682–689.
31. Philp D, Nguyen M, Scheremeta B, St-Surin S, Villa AM, et al. (2004)
Thymosin beta4 increases hair growth by activation of hair follicle stem cells.
FASEB J 18: 385–387.
32. Sosne G, Qiu P, Christopherson PL, Wheater MK (2007) Thymosin beta 4
suppression of corneal NFkappaB: a potential anti-inflammatory pathway. Exp
Eye Res 84: 663–669.
33. Sosne G, Siddiqi A, Kurpakus-Wheater M (2004) Thymosin-beta4 inhibits
corneal epithelial cell apoptosis after ethanol exposure in vitro. Invest
Ophthalmol Vis Sci 45: 1095–1100.
34. Baudy AR, Saxena N, Gordish H, Hoffman EP, Nagaraju K (2009) A robust in
vitro screening assay to identify NF-kappaB inhibitors for inflammatory muscle
diseases. Int Immunopharmacol 9: 1209–1214.
35. Sosne G, Chan CC, Thai K, Kennedy M, Szliter EA, et al. (2001) Thymosin
beta 4 promotes corneal wound healing and modulates inflammatory mediators
in vivo. Exp Eye Res 72: 605–608.
36. Reti R, Kwon E, Qiu P, Wheater M, Sosne G (2008) Thymosin beta4 is
cytoprotective in human gingival fibroblasts. Eur J Oral Sci 116: 424–430.
37. Zhang Y, Feurino LW, Zhai Q, Wang H, Fisher WE, et al. (2008) Thymosin
Beta 4 is overexpressed in human pancreatic cancer cells and stimulates
proinflammatory cytokine secretion and JNK activation. Cancer Biol Ther 7:
419–423.
38. Cavasin MA, Liao TD, Yang XP, Yang JJ, Carretero OA (2007) Decreased
endogenous levels of Ac-SDKP promote organ fibrosis. Hypertension 50:
130–136.
39. Pokharel S, van Geel PP, Sharma UC, Cleutjens JP, Bohnemeier H, et al. (2004)
Increased myocardial collagen content in transgenic rats overexpressing cardiac
angiotensin-converting enzyme is related to enhanced breakdown of N-acetyl-
Ser-Asp-Lys-Pro and increased phosphorylation of Smad2/3. Circulation 110:
3129–3135.
40. Mora CA, Baumann CA, Paino JE, Goldstein AL, Badamchian M (1997)
Biodistribution of synthetic thymosin beta 4 in the serum, urine, and major
organs of mice. Int J Immunopharmacol 19: 1–8.
Tb4 Treatment in Mdx Mice
PLoS ONE | www.plosone.org 6 January 2010 | Volume 5 | Issue 1 | e8976